Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia
Not Applicable
- Conditions
- Chronic myeloid leukemia
- Registration Number
- JPRN-UMIN000004798
- Lead Sponsor
- Keio University School of Medicine, Division of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)Has a history of AP/BC during TKI treatment 2)Cannot give written informed consent 3)Any patient whom the treating physician feels inappropriate for accrual
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse of chronic myeloid leukemia after discontinuation of tyrosine kinase inihibitors
- Secondary Outcome Measures
Name Time Method Change in QOL status, reduction of adverse events related to tyrosine kinase inhibitor treatment, reduction of economic burden